georgie18
2週前
CADL...$13.19...🥳...Watch for All Time highs here...
georgie18
Member Level
Re: georgie18 post# 32234
Thursday, February 20, 2025 10:01:31 AM
Post#
32302
of 32319
CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...
georgie18
Member Level
Re: georgie18 post# 178
Wednesday, February 19, 2025 11:56:55 AM
Post#
179
of 179
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...
georgie18
Member Level
Re: georgie18 post# 30792
Tuesday, February 18, 2025 9:52:58 AM
Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 160
Wednesday, January 22, 2025 10:41:18 AM
Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
2週前
CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...
georgie18
Member Level
Re: georgie18 post# 178
Wednesday, February 19, 2025 11:56:55 AM
Post#
179
of 179
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...
georgie18
Member Level
Re: georgie18 post# 30792
Tuesday, February 18, 2025 9:52:58 AM
Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 160
Wednesday, January 22, 2025 10:41:18 AM
Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
3週前
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...
georgie18
Member Level
Re: georgie18 post# 30792
Tuesday, February 18, 2025 9:52:58 AM
Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 160
Wednesday, January 22, 2025 10:41:18 AM
Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
3週前
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...
georgie18
Member Level
Re: georgie18 post# 160
Wednesday, January 22, 2025 10:41:18 AM
Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
3週前
CADL...$9.21...🥳
georgie18
Member Level
Re: georgie18 post# 673379
Friday, February 14, 2025 9:37:47 AM
Post#
674437
of 674573
CADL...$9.00...🥳...Been a nice easy mover...
georgie18
Member Level
Re: georgie18 post# 31532
Wednesday, February 05, 2025 10:22:33 AM
Post#
31578
of 32051
CADL...$8.07...🥳...moving beautifully...
georgie18
Member Level
Re: georgie18 post# 673244
Tuesday, February 04, 2025 3:06:34 PM
Post#
673314
of 673377
CADL...$7.86...🥳
georgie18
Member Level
Re: georgie18 post# 31467
Tuesday, February 04, 2025 11:00:49 AM
Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
3週前
CADL...$9.00...🥳...Been a nice easy mover...
georgie18
Member Level
Re: georgie18 post# 31532
Wednesday, February 05, 2025 10:22:33 AM
Post#
31578
of 32051
CADL...$8.07...🥳...moving beautifully...
georgie18
Member Level
Re: georgie18 post# 673244
Tuesday, February 04, 2025 3:06:34 PM
Post#
673314
of 673377
CADL...$7.86...🥳
georgie18
Member Level
Re: georgie18 post# 31467
Tuesday, February 04, 2025 11:00:49 AM
Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$8.07...🥳...moving beautifully...
georgie18
Member Level
Re: georgie18 post# 673244
Tuesday, February 04, 2025 3:06:34 PM
Post#
673314
of 673377
CADL...$7.86...🥳
georgie18
Member Level
Re: georgie18 post# 31467
Tuesday, February 04, 2025 11:00:49 AM
Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.86...🥳
georgie18
Member Level
Re: georgie18 post# 31467
Tuesday, February 04, 2025 11:00:49 AM
Post#
31487
of 31531
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.55...🥳...ANYBODY PAYING ATTENTION HERE...
georgie18
Member Level
Re: georgie18 post# 673062
Tuesday, February 04, 2025 9:43:19 AM
Post#
673223
of 673243
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.38...🥳...Beauty move as price catches up to the News...
georgie18
Member Level
Re: georgie18 post# 31276
Saturday, February 01, 2025 2:12:48 PM
Post#
31345
of 31466
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.07...🥳...Bullish Engulfing Candle Reversal signal...50/200 Crossed 100/200 ready to cross...Been loading under $7...Looking for Break/Hold of $14.85 and a run at $18 Record Highs...imo...we shall see...The price will catch up to the News...
georgie18
Member Level
Re: georgie18 post# 672206
Friday, January 31, 2025 10:28:50 AM
Post#
672943
of 673062
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.12...This price will soon catch up to the news...🥳Been loading under $7...
georgie18
Member Level
Re: georgie18 post# 30885
Thursday, January 23, 2025 3:25:24 PM
Post#
30907
of 31275
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.18...Hit $7.26...Hod...🥳
georgie18
Member Level
Re: georgie18 post# 671947
Thursday, January 23, 2025 2:03:43 PM
Post#
672171
of 672205
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
1月前
CADL...$7.07...🥳...HOD...Off the $6.60 range dip...
georgie18
Member Level
Re: tw0122 post# 30782
Wednesday, January 22, 2025 4:45:28 PM
Post#
30792
of 30884
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
2月前
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki
georgie18
Member Level
Re: None
Thursday, January 16, 2025 3:45:04 PM
Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
georgie18
2月前
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
rosemountbomber
2月前
No question PBM is a heavyweight in small biotech investing. And of course as you mention Paul Manning who leads them is on the board at Candel and just sank a bunch of money into buying shares personally it seems.
For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:
If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.
Will be watching this closely.
Dell_Griffith
3月前
Not ideal, that's for sure, but development stage, they don't have much of a choice. Did you check out the CMO? He was with Chimerix when it soared and was a solid Company. Left well before they fell apart.
The execs at Candel are solid. Whether they can get it done, is another story, of course.
Can't see a dip below 6, but seems to make sense to average down. Good luck, if you're in it.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
PonkenPlonken
1日前
Monksdream
3月前
Woodpecker3
3月前
